Price-to-Book

Affinia Therapeutics gets the green light for a human trial of AFTX-201, a one-time therapy for a devastating genetic heart disease, BAG3 DCM.

New 4-year real-world data shows Zevra's drug stabilizes the rare, fatal 'Childhood Alzheimer's' disease, marking a milestone for patients and families.

Atlanticus Holdings Corp. confirms its quarterly preferred stock dividend, highlighting a rare blend of FinTech innovation with reliable investor returns.

With a key drug for a rare disease nearing the finish line, Spruce adds two industry veterans to navigate the high-stakes FDA approval process.

As X4 Pharmaceuticals preps for a key investor summit, all eyes are on its pivotal trial for chronic neutropenia and the commercial fate of XOLREMDI®.

Morningstar's $365M CRSP acquisition and extended Vanguard pact positions it to challenge index titans, promising a new era for low-cost investing.

With home health aide costs nearing $78,000 annually, families face a financial maze. Learn key strategies for creating a realistic budget for senior care.

The oil & gas operator is one step from a NYSE listing, promising a 13.5% dividend yield and a major consolidation play in the mature assets market.

A new initiative from the Center for Educational Innovation aims to tackle the workforce readiness gap with AI, robotics, and teacher leadership training.

Ferguson Wellman projects a fourth year of market growth, defying skeptic fears, while navigating major wealth planning changes from the ‘Tax Act of 2025’.

With its radical solar car on the line, Aptera appoints a VW and BMW veteran as Chairman. Can traditional auto expertise finally launch a new era of efficiency?